1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Smith & Nephew Plc
  6. News
  7. Summary
    SN.   GB0009223206

SMITH & NEPHEW PLC

(SN.)
  Report
Delayed Quote. Delayed London Stock Exchange - 05/20 11:38:56 am
1274 GBX   +1.31%
05/05Berenberg Trims Smith & Nephew's PT, Keeps Buy Rating
MT
04/30SMITH & NEPHEW PLC : Monthly statement on outstanding equity shares and voting rights
CO
04/29European ADRs Nudge Higher in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Smith & Nephew : Jo Hallas joins Smith+Nephew's Board as Non-Executive Director

01/25/2022 | 05:07am EDT

25 January 2022

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce the appointment of Jo Hallas as a Non-Executive Director.

Ms Hallas is a Chartered Engineer with extensive international management experience focused on business transformation through both organic and acquisitive growth in global industrial and consumer sectors.

Since April 2019, she has served as Chief Executive Officer of FTSE250 business Tyman plc, a leading supplier to the construction industry. She was formerly Business Group Director for Spectris plc and prior to that held senior global commercial roles with Invensys, Bosch and Procter & Gamble. She was a Non-Executive Director of Norcros plc for seven years to 2019.

Ms Hallas holds an Engineering degree from the University of Cambridge and an MBA from INSEAD.

Roberto Quarta, Chair of Smith+Nephew, said:

"We are delighted to have secured a Board colleague with Jo's track record of driving growth and transformation whilst embedding sustainability and building corporate culture. I am confident that her expertise will further help us support the management team's strategic ambitions."

Jo Hallas will join the Board on 1 February 2022.

Enquiries

Investors

Andrew Swift

+44 (0) 1923 477433

Smith+Nephew

Media

Charles Reynolds

+44 (0) 1923 477314

Smith+Nephew

Susan Gilchrist / Ayesha Bharmal

+44 (0) 20 7404 5959

Brunswick

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations

Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

Disclaimer

Smith & Nephew plc published this content on 25 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 January 2022 10:06:03 UTC.


© Publicnow 2022
All news about SMITH & NEPHEW PLC
05/05Berenberg Trims Smith & Nephew's PT, Keeps Buy Rating
MT
04/30SMITH & NEPHEW PLC : Monthly statement on outstanding equity shares and voting rights
CO
04/29European ADRs Nudge Higher in Friday Trading
MT
04/29Citigroup Keeps Smith & Nephew At Neutral, Lifts PT
MT
04/29UBS Lifts Smith & Nephew PT, Keeps Neutral Rating
MT
04/28European ADRs Nudge Lower in Thursday Trading
MT
04/28Smith & Nephew plc Reports Revenue Results for the First Quarter of 2022
CI
04/28Standard Chartered leads FTSE 100 higher in earnings-driven session
RE
04/28TRANSCRIPT : Smith & Nephew plc, Q1 2022 Sales/ Trading Statement Call, Apr 28, 2022
CI
04/28SMITH & NEPHEW : +Nephew First Quarter 2022 Trading Update
PU
More news
Analyst Recommendations on SMITH & NEPHEW PLC
More recommendations
Financials (USD)
Sales 2022 5 338 M - -
Net income 2022 486 M - -
Net Debt 2022 2 086 M - -
P/E ratio 2022 28,1x
Yield 2022 2,22%
Capitalization 13 812 M 13 812 M -
EV / Sales 2022 2,98x
EV / Sales 2023 2,81x
Nbr of Employees 18 369
Free-Float 98,9%
Chart SMITH & NEPHEW PLC
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 15,86 $
Average target price 18,55 $
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Deepak S Nath Chief Executive Officer & Director
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Roberto Quarta Chairman
Vasant Padmanabhan President-Research & Development
Paul Connolly President-Global Operations
Sector and Competitors